Grant ID DP240091
Awarded On November 15, 2023
Title Gradalis, Inc. - Vigil maintenance in PS ovarian patients
Program Product Development Research
Award Mechanism Texas Therapeutics Company Awards for Product Development Research
Institution/Organization Gradalis, Inc.
Principal Investigator/Program Director John Nemunaitis
Cancer Sites Ovary
Contracted Amount $9,965,266*

*Pending contract negotiation

Lay Summary

An estimated 13,000 women will die of the disease in 2022. While most patients initially respond to treatment the majority will recur. While there have been strides made in the treatment of this disease, specifically in patients whose tumors harbor BRCA mutations or those that are BRCA-wt and have defective DNA repair (HRD) [22-24], there remains no specific treatment for patients with intact DNA repair (HRP). Vigil is a personalized immunotherapy [18, 19] that is made from the patient's own tumor. DNA is introduced into the tumor cells to promote an effective immune response against the cancer. The cells are irradiated so they are unable to replicate but are used to educate the immune syst...

Read More